Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 280-285

  Cannon, Nathan A ^a   Meyer, Jeffrey ^a   Iyengar, Puneeth ^a   Ahn, Chul ^b   Westover, Kenneth D ^a   Choy, Hak ^a   Timmerman, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Plastic Surgery University of Texas Southwestern   (United States)

Author keywords

Early stage; Inflammation; Non small cell lung cancer; Stereotactic radiation

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DEATH; EARLY STAGE NON SMALL CELL LUNG CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTE; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOSURGERY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84922229543     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000399     Document Type: Article

References (31)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Behtesda, MD: National Cancer Institute, 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/.
2. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444
4. Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395-400
5. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010;200:197-203
6. Botta C, Barbieri V, Ciliberto D, et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 2013;14:469-475
7. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012;14:864-869
8. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC Cancer 2013;13:158
9. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-428
10. Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011;18:3362-3369
11. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 2012;32:3535-3538
12. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?. Asian Pac J Cancer Prev 2013;14:5237-5242
13. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 2013;62:471-479
14. Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 2012;59:1687-1690
15. Liu H, Wu Y, Wang Z, et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis 2013;5:783-789
16. Szkandera J, Pichler M, Absenger G, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 2014;208:210-214
17. Wan S, Lai Y, Myers RE, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer 2013;44:293-304
18. Shah N, Parikh V, Patel N, et al. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the National Health and Nutrition Examination Survey-III. Int J Cardiol 2014;171:390-397
19. Turkmen K, Erdur FM, Ozcicek F, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in endstage renal disease patients. Hemodial Int 2013;17:391-396
20. Vermaelen K, Brusselle G. Exposing a deadly alliance: Novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther 2013;26:544-554
21. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008;43:374-379
22. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998
23. Dumitru CA, Gholaman H, Trellakis S, et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer 2011;129:859-869
24. Peng HH, Liang S, Henderson AJ, et al. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 2007;313:551-559
25. Wu Y, Zhao Q, Peng C, et al. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol 2011;225:438-447
26. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9:237-249
27. Philippe C, Philippe B, Fouqueray B, et al. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 1993;143:1713-1723
28. Tímár J, Tóvári J, Rásó E, Mészáros L, Bereczky B, Lapis K. Plateletmimicry of cancer cells: Epiphenomenon with clinical significance. Oncology 2005;69:185-201
29. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-134
30. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62:2824-2833
31. Demaria S, Formenti SC. Radiation as an immunological adjuvant: Current evidence on dose and fractionation. Front Oncol 2012;2:153